Belimumab added to rituximab for chronic immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older.
- You have primary immune thrombocytopenia (ITP) and it has lasted more than 2 months but less than 5 years since diagnosis.
- Your platelet count was low recently (≤30,000 per microliter in the last month, or <50,000 if you had bleeding or the doctor decided it still matters).
- Past treatment: steroids and/or IVIG helped at first but your platelet count dropped again after relapse.
- You have a past response to steroids/IVIG shown by a significant platelet rise (>30x10^9/L and at least double your baseline) followed by relapse.
- If you are a woman who could become pregnant: you must have a negative pregnancy test and use effective birth control without missing doses during the study and for 16 weeks after the last injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This study tests a new combination of two medicines—one that calms the immune system and one that helps your body make more platelets. It is for people with long-term ITP who have already tried other treatments and still have low platelet counts.
This trial tests a new drug (belantamab mafodotin) in adults with primary immune thrombocytopenia (ITP) who have already tried at least one other treatment. The goal is to see if the drug can safely raise platelet counts and reduce bleeding risk.
This trial tests whether adding a drug called orelabrutinib to high-dose dexamethasone (a steroid) works better than dexamethasone alone for treating newly diagnosed immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing very low blood counts. The goal is to see if the combination helps raise your platelet count and prevents bleeding.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This study tests whether adding a second medication (Iguratimod) to a lower dose of rituximab helps people with a blood condition called ITP who have not responded well to steroids. The goal is to see if the combination is more effective than rituximab alone at raising and keeping platelet counts stable.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.